Cargando…
Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents
Multiple sclerosis (MS) is one of the most frequently occurring disabling neurological disorders among young adults in Canada. It is a chronic inflammatory disorder of the central nervous system (CNS) that is thought to be immune mediated in nature. An estimated 55,000–75,000 Canadians suffer from t...
Autores principales: | Girouard, Nathalie, Soucy, Nanda |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063656/ https://www.ncbi.nlm.nih.gov/pubmed/21448467 http://dx.doi.org/10.2147/PPA.S10506 |
Ejemplares similares
-
Development of oral immunomodulatory agents in the management of multiple sclerosis
por: Nicholas, Richard, et al.
Publicado: (2011) -
Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010) -
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
por: Nicholas, Jacqueline Ann, et al.
Publicado: (2014) -
Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012) -
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)